 |
enisoprost |
|---|---|
| Trade Name | |
| Orphan Indication | 1. For use with cyclosporine in organ transplant recipients to reduce acute transplant rejection 2. For use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine. |
| USA Market Approval | USA |
| USA Designation Date | 1989-10-20 00:00:00 |
| Sponsor | G.D. Searle & Company;4901 Searle Parkway;Skokie, Illinois, 60077 |
